Investment Analysis
3 articles on Investment Analysis, researched and written by the Shotlee Editorial Team from primary sources.
Jim Cramer on Eli Lilly Amid Rival's GLP-1 Lawsuit
Jim Cramer weighs in on Eli Lilly's position in the GLP-1 market following a lawsuit from competitor Novo Nordisk, analyzing the situation for investors.
7 min read
Should You Invest in Novo Nordisk, the Ozempic Manufacturer, in 2026?
Investing in Novo Nordisk (NVO), the maker of Ozempic and Wegovy, has faced challenges recently, with shares declining. However, recent FDA approval of an oral form of Wegovy could change the company's trajectory. Analyzing competition and market dynamics is vital for investment decisions.
2 min read
Jim Cramer: Eli Lilly's GLP-1 Pill Will 'Revolutionize Everything'
Jim Cramer commented on Eli Lilly's GLP-1 pill, anticipating a revolutionary impact. He also assessed other portfolio holdings, including Taiwan Semi, Chevron, SL Green, and Microsoft, providing insights into their respective sectors.
2 min read